• 1
    Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010;125:S95S102.
  • 2
    Murphy P, Hillman T, Rajakulasingam K. Therapeutic targets for persistent airway inflammation in refractory asthma. Biomed Pharmacother 2010;64:140145.
  • 3
    Finkelman FD, Boyce JA, Vercelli D, Rothenberg ME. Key advances in mechanisms of asthma, allergy, and immunology in 2009. J Allergy Clin Immunol 2009;125:312318.
  • 4
    O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503508.
  • 5
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973984.
  • 6
    Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985993.
  • 7
    Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010;125:803813.
  • 8
    Allakhverdi Z, Allam M, Guimond A, Ferrari N, Zemzoumi K, Seguin R et al. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann NY Acad Sci 2006;1082:6273.
  • 9
    Allam M, Renzi PM. Inhibition of GM-CSF/IL-3/IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors. Antisense Nucleic Acid Drug Dev 2001;11:289300.
  • 10
    Allakhverdi Z, Allam M, Renzi PM. Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med 2002;165:10151021.
  • 11
    Fortin M, Ferrari N, Higgins M-E, Seguin S, Allam M, Allakhverdi Z et al. Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. Oligonucleotides 2006;16:203212.
  • 12
    Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008;177:952958.
  • 13
    Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21442148.
  • 14
    Cockcroft DW. Measure of airway responsiveness to inhaled histamine or metacholine; method of continuous aerosol generation and tidal breathing inhalation. In: HargreaveFE, WoolcockAJ, ed. Airway responsiveness: measurement and interpretation. Mississauga: Astra Publishing Canada Ltd, 1985:2228.
  • 15
    Cockcroft DW. Methacholine challenge methods. Chest 2008;134:678680.
  • 16
    O’Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740751.
  • 17
    Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264267.
  • 18
    Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308317.
  • 19
    Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R et al. Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for children six years of age and over, and adults. Can Respir J 2010;17:1524.
  • 20
    Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs 2008;13:643653.
  • 21
    Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2003;2:245259.
  • 22
    Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250257.
  • 23
    Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003;112:653665; quiz 666.
  • 24
    Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol 2008;180:11991206.
  • 25
    Kohno M, Yamasaki S, Tybulewicz VL, Saito T. Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 2005;105:20592065.
  • 26
    Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004;24:271281.
  • 27
    Siddiqui S, Mistry V, Doe C, Roach K, Morgan A, Wardlaw A et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008;122:335341, e331–333.
  • 28
    Margulis A, Nocka KH, Brennan AM, Deng B, Fleming M, Goldman SJ et al. Mast cell-dependent contraction of human airway smooth muscle cell-containing collagen gels: influence of cytokines, matrix metalloproteases, and serine proteases. J Immunol 2009;183:17391750.
  • 29
    Gajewska BU, Wiley RE, Jordana M. GM-CSF and dendritic cells in allergic airway inflammation: basic mechanisms and prospects for therapeutic intervention. Curr Drug Targets Inflamm Allergy 2003;2:279292.
  • 30
    De Lucca GV. Recent developments in CCR3 antagonists. Curr Opin Drug Discov Devel 2006;9:516524.
  • 31
    Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:45934601.
  • 32
    Dorman SC, Efthimiadis A, Babirad I, Watson RM, Denburg JA, Hargreave FE et al. Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis. Am J Respir Crit Care Med 2004;169:573577.
  • 33
    Radinger M, Lotvall J. Eosinophil progenitors in allergy and asthma – do they matter? Pharmacol Ther 2009;121:174184.
  • 34
    Lamkhioued B, Abdelilah SG, Hamid Q, Mansour N, Delespesse G, Renzi PM. The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol 2003;170:537547.
  • 35
    Gauvreau GM, Hessel EM, Boulet L-P, Coffman RL, O’Byrne PM. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174:1520.